Greenleaf Health LLC today announced that Andrew C. von Eschenbach, MD, who recently stepped down as Commissioner of the Food and Drug Administration (FDA), has joined the firm as Senior Advisor. Greenleaf Health is a full service regulatory consulting firm that provides strategic guidance to companies regulated by the FDA and companies developing innovative solutions to pressing public health problems around the globe. Dr. von Eschenbach, who resigned as FDA Commissioner in January after leading the agency since 2005, will offer strategic counsel to Greenleaf’s clients. Dr. von Eschenbach, an oncologist who previously served as director of the National Cancer Institute (NCI), will continue his leadership and advocacy on behalf of the cancer community by working to bring innovative treatments to patients, according to Patrick Ronan, Founder and President of Greenleaf Health. “Andy’s experience as a former FDA Commissioner and former director of the NCI, together with his decades of service as a cancer researcher and practicing oncologist, enables him to bring unparalleled experience and knowledge to Greenleaf Health,” Ronan said. “His addition to the firm sets Greenleaf apart with respect to the depth of knowledge about FDA decision-making, critical health policy matters and the global public health community.” “As I look forward to new opportunities to transform healthcare, I am pleased to contribute to Greenleaf’s efforts on behalf of the public health,” Dr. von Eschenbach said. “Working with Greenleaf’s clients to help them bring life-saving therapies to the patients and doctors who need them is one gratifying way for me to provide input on crucial health policy issues.”
